UChicago Medicine-led team selected for the 2022 Michael & Lori Milken Family Foundation-PCF Challenge Award to develop novel immunotherapy approaches in advanced prostate cancer

The Prostate Cancer Foundation (PCF) has awarded a $1 million grant to a renowned specialist at the University of Chicago Medicine Comprehensive Cancer Center.

Newly identified personalized immunotherapy combination treats an aggressive form of advanced prostate cancer

A combination treatment that targets the immune system helps treat aggressive prostate cancers that don’t respond to conventional therapies.

American College of Surgeons Experts Available to Speak on Concerning Trends in Advanced Prostate Cancer

CHICAGO: After two decades of decline, rates of advanced prostate cancer are on the rise, causing concern among physicians and healthcare organizations around the nation. American College of Surgeons (ACS) experts are available to help the media and public understand…

Hackensack Meridian JFK University Medical Center Offers Innovative PSMA PET Imaging Test to Aid in Diagnosis of Prostate Cancer

“The availability of the PYLARIFY test at JFK University Medical Center means patients with prostate cancer no longer need to travel to obtain PSMA-targeted PET imaging. They can get this innovative technology close to home,” said Amie Thornton, president, chief hospital executive, JFK University Medical Center.

‘Urology on the Beach’ Conference Highlights Advances in Research and Patient Care

From urologic cancers to female urology to male infertility to kidney stones and sexual health, top urologists from throughout the nation shared their insights and practical tips at “Urology on the Beach,” a conference hosted January 13-15 by the Desai Sethi Urology Institute at the University of Miami Miller School of Medicine.

Moffitt Researchers Develop Tool to Measure Patient Health and Well-Being after Radionuclide Therapy

Moffitt Cancer Center researchers have developed a tool to determine how a new class of prostate cancer therapies called radionuclide therapy (RNT) impacts patient-reported outcomes with the goal of using this information to guide treatment and improve quality of care. Their findings have been published in The Journal of Nuclear Medicine.

American Cancer Society Releases Latest Cancer Statistics, Launches Initiative to Address Prostate Cancer Resurgence and Disparities

Today, the American Cancer Society released Cancer Statistics, 2023, the organization’s annual report on cancer facts and trends. According to the report, overall cancer mortality has dropped 33% since 1991, averting an estimated 3.8 million cancer deaths. Based on ACS data, in 2023 there are projected to be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States.

Study Finds Providers Use Prostate Cancer Screening Tests, Even When They Provide Little Value to Patients

Prostate cancer is the second-leading cause of cancer death in men with more than 34,000 deaths in the U.S. each year, according to the American Cancer Society. But guidelines for prostate cancer screening are continually shifting, leading to uncertainty among patients and providers on when and if screening tests should be ordered. In a new study from Wake Forest University School of Medicine, researchers recently examined prostate screening testing among primary care providers and found that the tests are frequently used, even when they provide little value to patients.

New Study Shows Western Region has Highest Prostate Cancer Mortality Among White Men in U.S.; Black Men Face Highest Prostate Cancer Mortality Overall

New findings led by researchers at the American Cancer Society show the highest mortality rates for prostate cancer in White men were found in the Western region of the United States, including California, despite low incidence rates.

Study Reveals Pathways for Aggressive Prostate Cancer Subtype

The findings, which are the result of single-cell RNA-sequencing, were published in Nature Communications. The research was conducted in the lab of Paula Hurley, PhD, associate professor of Medicine and Urology. The researchers observed an interplay between the inherent properties of cancer cells and microenvironmental factors that contribute to this aggressive subtype of prostate cancer.

Metastasis-directed radiation therapy plus hormone therapy improves progression-free survival for men with advanced prostate cancer

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were presented today at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.

Radiation-hormone therapy combination may slow growth of oligometastatic prostate cancer

A new study offers a new option to patients with oligometastatic prostate cancer who want relief from hormone therapy without compromising the risk of their disease spreading. In the study, patients who received radiation in addition to intermittent hormone therapy lived longer without their disease progressing, and they were able to take longer breaks from the drug treatments. Results of the phase II trial (EXTEND; NCT03599765) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Lower prostate cancer screening rates associated with subsequent increase in advanced cancers

In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration (VA) medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.

Study Offers New Hope for Treatment-Resistant Prostate Cancer

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that they can circumvent a key mechanism in castration-resistant prostate cancer (CRPC) and possibly make immunotherapies more effective. By infusing nitric oxide (NO) into animal models, the team shrank tumors and paved the way for potential combination therapies. The study was published in Nature Cell Death & Disease.

Desai Sethi Urology Institute Draws Renowned Urologists, Researchers to Inaugural ‘Urology on the Beach’ Meeting, January 2023

The Desai Sethi Urology Institute at the University of Miami Miller School of Medicine will be hosting urology clinicians and scientists from today’s most prominent academic centers at the institute’s inaugural in-person “Urology on the Beach” meeting, January 13 to 15, 2023, at the Fontainebleau Hotel in Miami Beach.

Radiation oncology research and clinical trial results to be featured at ASTRO’s Annual Meeting in San Antonio

The American Society for Radiation Oncology (ASTRO) announced today the 10 studies that will be highlighted in the 2022 ASTRO Annual Meeting press program. Researchers will discuss their findings in two news briefings to be held October 24 and 25 in the Henry B. Gonzalez Convention Center in San Antonio and via live webcast. Reporters can register for the meeting at astro.org/annualmeetingpress.

Sylvester Game Changer Vehicle Among First in Nation to Offer Mobile Prostate Cancer Screening

Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine’s Game Changer vehicles, which bring health education and free screenings for many cancer types to South Florida communities in need, are for the first time offering prostate-specific antigen (PSA) screening for prostate cancer.

Mayo Clinic researchers identify drug resistance factors for advanced prostate cancer

In a new study published in Molecular Cancer Research, Mayo Clinic researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable and castration-resistant prostate cancer.

Genomic Testing Can Identify African American Prostate Cancer Patients Who Have High-Risk Disease

Moffitt Cancer Center has conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer. The study results were published in the Journal of the National Cancer Institute.

MD Anderson Research Highlights for July 27, 2022

Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients with lateral pelvic lymph node metastases in rectal cancer. Laboratory findings offer new understanding of the pancreatic cancer immune microenvironment, melanoma cell states, TP53 mutation status in acute myeloid leukemia (AML), and potential targets for metastatic prostate cancer and GNAS-mutant colorectal cancer.

Moffitt Study Shows Adaptive Therapy Improves Outcomes, Reduces Care Costs for Prostate Cancer Patients

Researchers in Center of Excellence for Evolutionary Therapy at Moffitt Cancer Center are thinking outside the box and studying an alternative approach called adaptive therapy that is based on evolutionary principles and mathematical modeling. In a new article in eLife, the researchers report updated results from a pilot clinical trial evaluating an adaptive therapy approach using the drug abiraterone to treat patients with metastatic castrate-resistant prostate cancer.

The Lancet Publishes Sylvester-Led Study Defining New Standard of Care for Prostate Cancer Recurrence After Prostatectomy

Adding short-term hormone therapy and pelvic lymph node radiotherapy to standard of care prostatectomy surgical bed treatment benefits prostate cancer patients whose prostate-specific antigen (PSA) levels are rising post prostatectomy, according to an international study led by Alan Pollack, M.D.,…

Moffitt Researchers Contribute to Discovery of Mechanism Leading to Drug Resistance in Prostate Cancer

In a new article published in Science Translational Medicine, Moffitt Cancer Center researchers reveal a mechanism by which prostate cancer cells become resistant through molecular modification of the androgen receptor protein and identify a potential treatment approach that could overcome this resistance.

Radiation Therapy as Effective as Surgery for Prostate Cancer

Radiation is an effective treatment for prostate cancer. Ronald D. Ennis, MD,Professor and Vice Chair of Network Integration and Quality, Department of Radiation Oncology at Rutgers Cancer Institute, along with Lara Hathout, MD, FRCPC, radiation oncologist and director of Brachytherapy at Rutgers Cancer Institute and associate Professor of radiation oncology at Rutgers Robert Wood Johnson Medical School share more

Henry Ford Health is First in the World to Offer Latest Advancement in MR-Guided Radiation Therapy

Henry Ford Health is the first in the world to complete a full course of patient treatments using the latest advancement in magnetic resonance (MR)-guided radiation therapy, which integrates real-time magnetic resonance imaging (MRI) and linear acceleration to deliver precise and accurate radiation treatment more rapidly than ever before.

New Combined Therapy Helps Extend Lives of Men With Prostate Cancer

Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy—a commonly used hormone injection—plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years. The findings were published in the peer-reviewed journal The Lancet.